Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
IPO Year: 2019
Exchange: NASDAQ
Website: kaleido.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/31/2022 | $11.00 → $3.00 | Buy | Chardan Capital |
| 11/12/2021 | $15.00 → $11.00 | Buy | Chardan Capital |
| 11/3/2021 | $25.00 → $22.00 | Market Outperform | JMP Securities |
| 10/19/2021 | $3.00 | Equal-Weight → Underweight | Morgan Stanley |
For Immediate Release: September 07, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: As part of the FDA’s effort to protect consumers, the agency issued a warning letter to Kaleido Biosciences, Inc. for not complying with federal laws and regulations, including laws and regulations to protect individuals participatin
15-12B - Kaleido Biosciences, Inc. (0001751299) (Filer)
EFFECT - Kaleido Biosciences, Inc. (0001751299) (Filer)
S-8 POS - Kaleido Biosciences, Inc. (0001751299) (Filer)
S-8 POS - Kaleido Biosciences, Inc. (0001751299) (Filer)
S-8 POS - Kaleido Biosciences, Inc. (0001751299) (Filer)
POS AM - Kaleido Biosciences, Inc. (0001751299) (Filer)
25 - Kaleido Biosciences, Inc. (0001751299) (Filer)
8-K - Kaleido Biosciences, Inc. (0001751299) (Filer)
NT 10-K - Kaleido Biosciences, Inc. (0001751299) (Filer)
8-K - Kaleido Biosciences, Inc. (0001751299) (Filer)